Prime Medicine Announces Preclinical Data and 2023 Strategic Priorities at J.P. Morgan Healthcare Conference

Prime Medicine, Inc.

New preclinical data in Friedrich's ataxia and cystic fibrosis show restoration of genetic function via Prime Editing.
Preliminary off-target safety analyses in Wilson's disease and CGD detected no guide-dependent editing across 170 and 550 sites, respectively.
PASSIGE technology achieved ~60% precise insertion of a 3.5 kb transgene into primary human T cells in a one-step non-viral process.
LNP delivery to rodent liver achieved >40% editing of PCSK9 gene and >90% reduction in serum PCSK9 protein.
Company expects to nominate first development candidate for CGD in Q1 2023 and file first IND as early as 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.